Titan Bio-tech Ltd

BSE: 524717

₹ 326-21.85%refreshed 23 Oct, 03:30 pm ISTMarket cap: ₹ 1,684 crWebsite: www.titanbiotechltd.comUpdated: 24 Oct 2026

About

Titan Biotech Ltd manufactures and sells biological products - primarily microbiological culture media under the TM Media brand, along with nutraceuticals and specialty biological ingredients - for research, pharmaceutical, food, agricultural and industrial applications. The company is described as leading the way in the Indian microbiological culture media industry.^[1][2]

Business segments

The company operates as a single primary business segment: Biological Products, covering culture media, nutraceuticals and related biological ingredients. No sub-segment split is reported for management purposes.^[1]
Domestic revenue was Rs. 12,585.83 lakhs in FY26, up from Rs. 10,254.80 lakhs in FY25.^[1]
Overseas (export) revenue was Rs. 8,033.20 lakhs in FY26, up from Rs. 5,390.28 lakhs in FY25.^[1]

Products and brands

Culture media products are marketed under the TM Media brand and include dehydrated culture media, ready-to-use culture media (petri dish format), chromogenic and specialised media, and raw materials such as peptones and agars.^[1]
The broader portfolio also includes nutraceutical products and other biological products serving research, pharmaceutical, food, agricultural and industrial applications.^[1]

Customers and end-markets

Domestic customers include hospitals and diagnostic labs (clinical microbiology), food, pharma and biotech industries (industrial microbiology), and research institutions.^[1]
The company also serves international customers; the global biotech, nutraceutical and microbiological culture media market is described as open with immense opportunity.^[1]

Exports

Goods exported totalled Rs. 8,033.20 lakhs in FY26. Goods imported were Rs. 862.78 lakhs. A foreign exchange gain of Rs. 190.20 lakhs was recorded in FY26.^[1]
The company does not hedge its foreign exchange receivables or payables and is not exposed to commodity price risk.^[1]

Workforce

Permanent employees on rolls were 527 as at 31 March 2026, an increase of 15.09% during FY26.^[1]
Permanent employees were 424 as at 31 March 2025, a 7.07% increase during FY25.^[3]

Recent corporate actions

Members approved a stock split in FY26: 1 equity share of Rs. 10 face value subdivided into 5 shares of Rs. 2 face value each; record date was 20 February 2026.^[1]
Dividend declared at 25% for FY26 (Rs. 0.50 per share post-split), due for IEPF transfer in November 2033.^[1]
No capital was raised through preferential allotment or qualified institutions placement during FY26.^[1]
Investments in debt instruments stood at Rs. 3,328.78 lakhs at FY26 year-end, up from Rs. 813.10 lakhs in the prior year.^[1]

Market Cap

₹1,684 Cr

High / Low

₹556 / 171

Stock P/E

51.1

Price / Book

9.6

Book Value

₹44

EPS

₹7.2

No. of Shares

4.13 Cr

ROCE

24.4%

ROE

17.8%

OPM

18.5%

Debt / Equity

0.02

Sales

₹206 Cr

Net Profit

₹30 Cr

Promoter holding

55.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

No earnings calls are on record for this company, so our models read its annual report and financials end-to-end - then value the business and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
P&L bridge from reported history - worst / average / best multiple cases.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials